Alpha 2.0
Login Register
» Authors » Maurizia Brunetto

Maurizia Brunetto

Explore the profile of Maurizia Brunetto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 1526
Followers 0
Related Specialties
Gastroenterology
General Medicine
Allergy & Immunology
Top 10 Co-Authors
Piero Colombatto
Markus Cornberg
Maria Buti
Pietro Lampertico
John F Flaherty
Ferruccio Bonino
Calvin Q Pan
Kosh Agarwal
Henry L Y Chan
Pietro Invernizzi
Published In
J Hepatol
Clin Gastroenterol Hepatol
Dig Liver Dis
PLoS One
JHEP Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, et al.
Clin Gastroenterol Hepatol . 2024 Dec; PMID: 39674236
Background & Aims: Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease...
2.
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration
Rosato V, Nevola R, Dallio M, Di Micco P, Spinetti A, Zeneli L, et al.
J Clin Med . 2024 Oct; 13(19). PMID: 39407867
Direct oral anticoagulants (DOACs) are recommended for the management of thrombosis prophylaxis, especially in patients with atrial fibrillation. As substrates of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein, they are implicated...
3.
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic
Tramonti Fantozzi M, Ceccarelli L, Petri D, De Vita E, Agostini A, Colombatto P, et al.
J Viral Hepat . 2024 Jul; 31(10):623-632. PMID: 39072924
HCV infection poses a global health threat, with significant morbidity and mortality. This study examines HCV trends in a large Italian region from 2015 to 2022, considering demographic changes, evolving...
4.
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
De Vincentis A, Ampuero J, Terracciani F, DAmato D, Gerussi A, Cristoferi L, et al.
Clin Gastroenterol Hepatol . 2024 May; 22(10):2062-2074.e11. PMID: 38782175
Background & Aims: Obeticholic acid (OCA) is the only licensed second-line therapy for primary biliary cholangitis (PBC). With novel therapeutics in advanced development, clinical tools are needed to tailor the...
5.
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
J Hepatol . 2024 May; 81(4):621-629. PMID: 38734383
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week...
6.
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States
Toumi M, Wallace J, Cohen C, Marshall C, Kitchen H, Macey J, et al.
BMC Public Health . 2024 Feb; 24(1):611. PMID: 38408941
Background: People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma. Methods: Adults...
7.
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Lim Y, Chan H, Ahn S, Seto W, Ning Q, Agarwal K, et al.
JHEP Rep . 2023 Sep; 5(10):100847. PMID: 37771546
Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir...
8.
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
Sonneveld M, Chiu S, Park J, Brakenhoff S, Kaewdech A, Seto W, et al.
Gastroenterology . 2023 Sep; 166(1):168-177.e8. PMID: 37769952
Background & Aims: Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up. Methods: We studied the association between hepatitis...
9.
An Unexpected Case of Infection Revealed during Liver Transplantation
Mangano V, Campani D, Cacciato Insilla A, Coco B, Gomez Morales M, Brunetto M, et al.
Pathogens . 2023 Aug; 12(8). PMID: 37623963
A man with hepatitis B infection was admitted to Pisa University Hospital for hepatological evaluation, which revealed multiple cystic lesions and suggested a cirrhotic evolution. Treatment with Entecavir 0.5 mg/day...
10.
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Chan H, Buti M, Lim Y, Agarwal K, Marcellin P, Brunetto M, et al.
Am J Gastroenterol . 2023 Aug; 119(3):486-496. PMID: 37561058
Introduction: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior...